Contrave Case Splits US Court In Pyrrhic Victory For Teva

 
• By Aidan Fry
  
2030
teva has failed to invalidate a US patent that protects the Contrave combination weight-loss drug until February 2030 • Source: Shutterstock

More from Legal & IP

More from Generics Bulletin